1h Free Analyst Time
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 - Drugs In Development, 2022, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease, Mouth and Dental Disorders, Musculoskeletal Disorders, Oncology and Respiratory which include indications Autoimmune Disorders, Alzheimer's Disease, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Huntington Disease, Parkinson's Disease, Allergic Asthma, Amyotrophic Lateral Sclerosis, Arthritis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Bullous Pemphigoid, Chronic Inflammation, Churg-Strauss Syndrome, Glomerulonephritis, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Inflammatory Pain, Kidney Disease (Nephropathy), Lupus Nephritis, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Motor Neuron Diseases, Neuroinflammation, Neuropathic Pain (Neuralgia), Neutropenia, Pain, Periodontitis, Peritonitis, Solid Tumor and Transplant Rejection.
Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
- C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
- C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
- C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
- C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
- C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
- Featured News & Press Releases
- Aug 24, 2022: ChemoCentryx announces TAVNEOS (avacopan) presentations at upcoming medical conferences
- Aug 18, 2022: UK NICE recommends Vifor’s Tavneos for AAV treatment
- May 31, 2022: Chemocentryx announces abstracts of TAVNEOS to be presented at June rheumatology, oncology and nephrology conferences
- May 18, 2022: ChemoCentryx announces presentation at the society for investigative dermatology meeting highlighting the role of tunnels in driving ongoing disease in hidradenitis suppurativa
- May 11, 2022: ChemoCentryx announces upcoming conference abstracts focused on TAVNEOS (avacopan) and the burden of systemic glucocorticoid use in ANCA-asociated vasculitis
- Apr 21, 2022: Health Canada approves Vertex’s Trikafta for cystic fibrosis in children
- Jan 19, 2022: ChemoCentryx announces EU approval of TAVNEOS (avacopan) for the treatment of ANCA-associated vasculitis
- Jan 10, 2022: InflaRx announces new pipeline program - oral C5aR inhibitor
- Nov 12, 2021: VFMCRP receives positive CHMP opinion for Tavneos for the treatment of ANCA-associated vasculitis
- Nov 04, 2021: Abstracts at the annual meetings of the American Society of Nephrology and American College of Rheumatology highlight potential value of TAVNEOS (avacopan)
- Oct 14, 2021: PANTHERx Rare Pharmacy selected by ChemoCentryx to distribute TAVNEOS (avacopan) in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
- Oct 13, 2021: Amber Specialty Pharmacy selected by ChemoCentryx to dispense TAVNEOS (avacopan), an adjunctive treatment for ANCA-associated vasculitis
- Oct 08, 2021: ChemoCentryx announces FDA approval of TAVNEOS (avacopan) in ANCA-Associated Vasculitis
- Sep 27, 2021: VFMCRP announces approval for TAVNEOS (avacopan) for the treatment of ANCA-associated vasculitis in Japan
- Jul 06, 2021: Innate Pharma to stop development of avdoralimab for Covid-19
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Alsonex Pty Ltd, 2022
- Pipeline by ChemoCentryx Inc, 2022
- Pipeline by Dompe Farmaceutici SpA, 2022
- Pipeline by InflaRx NV, 2022
- Pipeline by Innate Pharma SA, 2022
- Pipeline by MorphoSys AG, 2022
- Pipeline by Prommune Inc, 2022
- Pipeline by Teva Pharmaceutical Industries Ltd, 2022
- Pipeline by Visterra Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alsonex Pty Ltd
- ChemoCentryx Inc
- Dompe Farmaceutici SpA
- InflaRx NV
- Innate Pharma SA
- MorphoSys AG
- Prommune Inc
- Teva Pharmaceutical Industries Ltd
- Visterra Inc
